Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of A166 in HER2-positive unresectable or metastatic breast cancer after prior topoisomerase I payload HER2 ADC
CTR20242261Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab botidotin in breast cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Sep 2024; status: active.
02
Drugs
trastuzumab botidotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20242261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242261.